Current Press Releases

Keyword Search
 
Recent Press Releases | Archived Press Releases
DateTitle 
08/09/17Pacira Pharmaceuticals to Present at the 2017 Wedbush Pacgrow Healthcare Conference
PARSIPPANY, N.J., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the 2017 Wedbush Pacgrow Healthcare Conference at 9:10 AM ET on Tuesday, August 15, 2017 in New York City. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Paci... 
Printer Friendly Version
08/02/17Pacira Pharmaceuticals, Inc. Reports Second Quarter 2017 Financial Results
-- EXPAREL® Net Product Sales Up 6% Year-Over-Year -- -- Full-year EXPAREL net product sales guidance of $290 to $310 million reiterated -- -- Conference Call Today at 8:30 a.m. ET -- PARSIPPANY, N.J., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced consolidated financial results for the second quarter ended June 30, 2017. “We are pleased to report another quarter of solid EXPAREL growth and remain on track to deliver our full-year financial gui... 
Printer Friendly Version
07/26/17Pacira Announces Publication of Phase 4 Study of EXPAREL in Patients Undergoing Total Knee Replacement in The Journal of Arthroplasty
PILLAR study demonstrated a 78 percent decrease in opioid consumption and significantly better pain control with infiltration of EXPAREL plus bupivacaine versus bupivacaine alone Ten percent of patients in the EXPAREL arm required no opioids for pain control PARSIPPANY, N.J., July 26, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced the publication of its Phase 4 PILLAR study of EXPAREL® (bupivacaine liposome injectable suspension) in total knee arthroplast... 
Printer Friendly Version
07/25/17Pacira Pharmaceuticals Announces Timing for Second Quarter 2017 Financial Results Webcast and Conference Call
PARSIPPANY, N.J., July 25, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results before the open of the U.S. markets on Wednesday, August 2, 2017. The announcement will be followed by a conference call at 8:30 a.m. ET. Participating in the call from Pacira will be Dave Stack, chairman and chief executive officer, and other members of the company’s senior management team. The call can be accessed by dialin... 
Printer Friendly Version
07/25/17Pacira Announces Topline Phase 3 Results for EXPAREL® as a Single-dose Nerve Block
Upper extremity study showed that EXPAREL significantly reduces pain scores and opioid use Lower extremity study defined safety and pharmacokinetic profile through 120 hours Timing for resubmission of supplemental New Drug Application remains on track Conference call scheduled for today at 8:30 AM ET PARSIPPANY, N.J., July 25, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced the completion of two Phase 3 placebo-controlled studies evaluating the effica... 
Printer Friendly Version
06/15/17Pacira Pharmaceuticals Appoints Mark I. Froimson, M.D., to Board of Directors
PARSIPPANY, N.J., June 15, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced the appointment of Mark I. Froimson, M.D. to its board of directors. Dr. Froimson is currently serving as the President of the American Association of Hip and Knee Surgeons (AAHKS). Previously, he was the Executive Vice President and Chief Clinical Officer of Trinity Health, a major national non-profit Catholic healthcare system comprising 93 hospitals in 22 states. “Mark’s deep cl... 
Printer Friendly Version
06/14/17Pacira Pharmaceuticals to Present at the JMP Securities Life Sciences Conference
PARSIPPANY, N.J., June 14, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the JMP Securities Life Sciences Conference at 3:00 PM ET on Tuesday, June 20, 2017 in New York City. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira we... 
Printer Friendly Version
06/01/17Pacira Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference
PARSIPPANY, N.J., June 01, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the Jefferies 2017 Global Healthcare Conference at 1:30 PM ET on Tuesday, June 6, 2017 in New York City. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira... 
Printer Friendly Version
05/23/17Pacira Pharmaceuticals Announces Resignation of James Scibetta
PARSIPPANY, N.J., May 23, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that James Scibetta is resigning as the company’s president to become chief executive officer of an undisclosed private early-stage oncology company. Pacira will allocate Mr. Scibetta’s operational oversight responsibilities to the current leadership team and does not intend to name a successor. Mr. Scibetta will remain with the company through June 30 to ensure a seamless transition p... 
Printer Friendly Version
05/10/17Pacira Pharmaceuticals to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference
PARSIPPANY, N.J., May 10, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the Bank of America Merrill Lynch 2017 Healthcare Conference at 8:00 AM PT on Wednesday, May 17, 2017 in Las Vegas. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on ... 
Printer Friendly Version
05/04/17Pacira Pharmaceuticals, Inc. Reports First Quarter 2017 Financial Results
-- EXPAREL® Net Product Sales Up 6% Year-Over-Year -- -- Conference Call Today at 8:30 a.m. ET -- PARSIPPANY, N.J., May 04, 2017 (GLOBE NEWSWIRE) --  Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today provided updates on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the first quarter ended March 31, 2017. “We’re pleased with our strong first quarter highlighted by important strategic advances a... 
Printer Friendly Version
05/03/17New Research Shows Vast Majority of Oral Surgery Patients Would Choose Non-opioid Medication to Treat Postsurgical Pain if Given the Option
Patients and their parents willing to pay more for an opioid alternative following wisdom tooth extraction to avoid side effects and risk of addiction     PARSIPPANY, N.J., May 03, 2017 (GLOBE NEWSWIRE) -- According to a new national survey of over 1,500 oral surgery patients or their parents, more than seven in 10 respondents indicated they would opt for a non-opioid medication to treat postsurgical pain from third molar (wisdom tooth) extraction if given the choice. Approximately 80 percent... 
Printer Friendly Version
04/27/17Pacira Pharmaceuticals Announces Timing for First Quarter 2017 Financial Results Webcast and Conference Call
PARSIPPANY, N.J., April 27, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter financial results before the open of the U.S. markets on Thursday, May 4, 2017. The announcement will be followed by a conference call at 8:30 a.m. ET. Participating in the call from Pacira will be Dave Stack, chairman and chief executive officer, and other members of the company’s senior management team. The call can be accessed by dialing 1-... 
Printer Friendly Version
04/03/17Pacira Pharmaceuticals, Inc. to Present at the Needham Healthcare Conference
PARSIPPANY, N.J., April 03, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the 16th Annual Needham Healthcare Conference at 3:00 PM ET on Tuesday, April 4, 2017, in New York. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira web... 
Printer Friendly Version
03/16/17Trinity Health and Pacira Pharmaceuticals Announce Collaboration to Decrease Opioid Use Nationwide
Collaboration will develop and standardize evidence-based, low-opioid strategies across Trinity Health's 22 states to benefit people and communities PARSIPPANY, N. J. and LIVONIA, Mich., March 16, 2017 (GLOBE NEWSWIRE) -- Trinity Health, one of the largest hospital systems in the nation, and Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX), today announced they will collaborate to develop an alternative approach to opioids for pain management. ... 
Printer Friendly Version
03/14/17Phase 4 Study Shows EXPAREL® Versus an Active Comparator Significantly Reduces Opioid Consumption and Postsurgical Pain in Patients Undergoing Total Knee Arthroplasty
Multicenter randomized study serves as unequivocal evidence of EXPAREL as an opioid minimizing agent in a complex and painful surgical procedure Protocol’s best practice infiltration technique for the use of EXPAREL will be focus of educational programs at American Academy of Orthopaedic Surgeons Annual Meeting PARSIPPANY, N.J. , March 14, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) announced that its Phase 4 study of EXPAREL® (bupivacaine liposome injectable suspensi... 
Printer Friendly Version
03/13/17Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference
PARSIPPANY, N.J., March 13, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that its management team is scheduled to present at the Barclays Global Healthcare Conference at 10:15 a.m. ET on Thursday, March 16, 2017, in Miami. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two w... 
Printer Friendly Version
03/07/17Pacira Pharmaceuticals Announces Pricing of $300 Million Aggregate Principal Amount of 2.375% Convertible Senior Notes due 2022
PARSIPPANY, N.J., March 07, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (Nasdaq:PCRX) today announced the pricing of $300 million aggregate principal amount of convertible senior notes due 2022 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).  Pacira also granted the initial purchasers of the notes a 30-day option to purchase up to an additional $45 million aggregate princ... 
Printer Friendly Version
03/06/17Pacira Pharmaceuticals Announces Proposed Offering of $300 Million Aggregate Principal Amount of Convertible Senior Notes
PARSIPPANY, N.J., March 06, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (Nasdaq:PCRX) today announced that it intends to offer, subject to market and other conditions, $300 million aggregate principal amount of convertible senior notes due 2022 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).  Pacira also intends to grant the initial purchasers of the notes a 30-day option... 
Printer Friendly Version
03/01/17Pacira Pharmaceuticals Reports 2016 Financial Results and Provides Business Update
-- Phase 4 EXPAREL® study in total knee arthroplasty meets co-primary endpoints for pain control and opioid reduction against an active comparator -- -- EXPAREL net product sales up 11% year-over-year -- -- EXPAREL net product sales expected to be in the range of $290 to $310 million in 2017 -- -- Conference call today at 8:30 a.m. ET -- PARSIPPANY, N.J., March 01, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today reported financial results for 2016 and its outlook ... 
Printer Friendly Version
02/16/17Pacira Pharmaceuticals Announces Timing for 2016 Financial Results Webcast and Conference Call
PARSIPPANY, N.J., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s fourth quarter and year ended December 31, 2016 will be released before the market opens on Wednesday, March 1, 2017. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Wednesday, March 1, 2017, at 8:30 a.m. ET. The call can be accessed by dialing 1-877-845-0... 
Printer Friendly Version
02/15/17Pacira Pharmaceuticals, Inc. to Present at the 2017 RBC Capital Markets’ Healthcare Conference
PARSIPPANY, N.J., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Pacira Pharmaceuticals management team is scheduled to participate in an analyst-led fireside chat at the 2017 RBC Capital Markets’ Healthcare Conference at 10:00 a.m. ET on Wednesday, February 22, 2017, in New York. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A... 
Printer Friendly Version
01/25/17Pacira Pharmaceuticals Announces Collaboration with DePuy Synthes to Support Promotion, Education and Training of EXPAREL® in Orthopedics
– Collaboration will focus on opportunities in joint reconstruction, spine, sports medicine and trauma specialties – – Conference call today at 8:30 a.m. ET – PARSIPPANY, N.J., Jan. 25, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced the initiation of an agreement with DePuy Synthes Sales Inc. to market and promote the use of EXPAREL® (bupivacaine liposome injectable suspension) for orthopedic procedures in the United States market. With the opioid epid... 
Printer Friendly Version
01/06/17Pacira Pharmaceuticals Reports Preliminary 2016 Revenues of $276.4 Million
EXPAREL net product sales driven by soft tissue and orthopedic procedures PARSIPPANY, N.J., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today reported preliminary unaudited total revenues and EXPAREL® (bupivacaine liposome injectable suspension) net product sales for the fourth quarter and full-year 2016.  “2016 was a year of solid execution that has set the stage for continued growth of EXPAREL,” said Dave Stack, chief executive officer and chairman of Pac... 
Printer Friendly Version
01/03/17Pacira Pharmaceuticals, Inc. to Present at the 35th Annual J.P. Morgan Healthcare Conference
PARSIPPANY, N.J., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Dave Stack, Chief Executive Officer and Chairman of Pacira Pharmaceuticals, is scheduled to present at the 35th Annual J.P. Morgan Healthcare Conference at 3:30 p.m. PT (6:30 p.m. ET) on Monday, January 9, 2017, in San Francisco. Mr. Stack is expected to present an overview of the company. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investo... 
Printer Friendly Version
11/29/16Pacira Pharmaceuticals and GeneAlign Announce Partnership to Develop Low-Opioid Pain Management Protocols for Postsurgical Patients at High Risk of Addiction
Collaboration will leverage genetic testing to identify patients predisposed to developing addiction following opioid exposure PARSIPPANY, N.J., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced a joint endeavor with GeneAlign, a therapeutic management and solutions company working to revolutionize personalized medicine through a patient-specific opioid risk assessment program that includes behavioral surveys, educational tools and genetic testing. U... 
Printer Friendly Version
11/22/16American College of Surgeons Launches Education Program on Opioids and Surgery: Use, Abuse, and Alternatives
Pacira grant will allow for the development and distribution of resources to educate patients and surgeons on opioid use in surgical care CHICAGO, Nov. 22, 2016 (GLOBE NEWSWIRE) -- The American College of Surgeons (ACS) today announced a new multifaceted initiative to improve the knowledge and management of pain in surgical patients with a focus on opioid risk and non-opioid alternatives. With an educational grant from Pacira Pharmaceuticals, Inc. (Pacira), ACS will develop Opioids and Sur... 
Printer Friendly Version
11/11/16Pacira Pharmaceuticals Unveils Virtual Reality Training Simulation to Enhance Administration Technique Education for EXPAREL® in Total Knee Replacement Surgery
3D Mobile Simulation Will Also Debut in Pacira Booth #907 at AAHKS 2016 PARSIPPANY, N.J., Nov. 11, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today introduced a revolutionary new virtual reality simulation intended to provide clinicians with an immersive, hands-on training experience to reinforce the recommended technique for administering EXPAREL (bupivacaine liposome injectable suspension) in total knee arthroplasty (TKA) based on the infiltration protocol developed... 
Printer Friendly Version
11/10/16Correction: Pacira Pharmaceuticals, Inc. to Present at Investor Conferences in November
PARSIPPANY, N.J., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that senior leadership is scheduled to present an overview of the company at the following investor conferences in November: Jefferies 2016 London Healthcare Conference at 2:00 p.m. GMT (9:00 a.m. ET) in London on Thursday, November 17, 2016. 28th Annual Piper Jaffray Healthcare Conference at 11:00 a.m. ET in New York on Tuesday, November 29, 2016. Live audio webcasts of ... 
Printer Friendly Version
11/10/16Pacira Pharmaceuticals, Inc. to Present at Investor Conferences in November
PARSIPPANY, N.J., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that senior leadership is scheduled to present an overview of the company at the following investor conferences in November: Jefferies 2016 London Healthcare Conference at 2:00 p.m. GMT (7:00 p.m. ET) in London on Thursday, November 17, 2016. 28th Annual Piper Jaffray Healthcare Conference at 11:00 a.m. ET in New York on Tuesday, November 29, 2016. Live audio webcasts of ... 
Printer Friendly Version
11/02/16Pacira Pharmaceuticals, Inc. Reports Third Quarter 2016 Financial Results
-- Total Net Revenues Up 10% Year-Over-Year -- -- EXPAREL® Net Product Sales Up 9% Year-Over-Year -- -- Conference Call Today at 9 a.m. ET -- PARSIPPANY, N.J., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today provided updates on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the third quarter ended September 30, 2016. “EXPAREL revenues continued to grow year-... 
Printer Friendly Version
10/20/16Pacira Pharmaceuticals Continues to Build Out Robust Commercial Leadership Team
Company Appoints Thomas Sluby as Vice President, Sales and Matthew Lehmann as Vice President, Marketing PARSIPPANY, N.J., Oct. 20, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced the appointment of two key individuals who will assume leadership roles within the company’s commercial organization. Thomas Sluby has been named Vice President, Sales and Matthew Lehmann has been appointed Vice President, Marketing – Emerging Therapies; both individuals will repor... 
Printer Friendly Version
10/17/16Pacira Pharmaceuticals Announces Timing for Third Quarter 2016 Financial Results Webcast and Conference Call
PARSIPPANY, N.J., Oct. 17, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s third quarter ended September 30, 2016 will be released before the market opens on Wednesday, November 2, 2016. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Wednesday, November 2, 2016, at 9 a.m. ET. The call can be accessed by dialing 1-877-845-0779 (d... 
Printer Friendly Version
09/21/16Pacira Pharmaceuticals Announces Official Launch of EXPAREL to the Oral Surgeon Community to Treat Pain Following Oral and Maxillofacial Procedures
New research presented at AAOMS 2016 shows EXPAREL is safe and effective for pain relief following removal of wisdom teeth PARSIPPANY, N.J., Sept. 21, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced new data regarding the benefit of EXPAREL® (bupivacaine liposome injectable suspension) for patients undergoing third molar (wisdom teeth) extraction, marking the official launch of the product to the oral surgeon community. EXPAREL is a local analgesic that pro... 
Printer Friendly Version
09/01/16Pacira Pharmaceuticals, Inc. to Present at the Morgan Stanley Global Healthcare Conference
PARSIPPANY, N.J., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Dave Stack, Chief Executive Officer and Chairman of Pacira Pharmaceuticals, is scheduled to present at the Morgan Stanley Global Healthcare Conference at 11:05 a.m. ET on Monday, September 12, 2016, in New York. Mr. Stack is expected to present an overview of the company. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” sec... 
Printer Friendly Version